| Document |
Document Title |
|
WO/2023/120704A1 |
The present disclosure provides a composition that is for improving a heart function and that contains a compound represented by formula (I), or an ester, oxide, prodrug, pharmaceutically acceptable salt or solvate thereof. Also provided...
|
|
WO/2023/120405A1 |
The purpose of the present invention is to provide a composition for minimizing the production and/or accumulation of amyloid β. The present invention relates to a composition for minimizing the production and/or accumulation of amyloid...
|
|
WO/2023/120376A1 |
The purpose of the present invention is to provide an oral composition which contains ergothioneine or a salt thereof and a cereal oil or γ-oryzanol and in which the bitterness derived from ergothioneine or the salt thereof and the odor...
|
|
WO/2023/120557A1 |
The present description discloses a packaged body of reduced coenzyme Q10, which eliminates the need for formulating the reduced coenzyme Q10 into a preparation, does not undergo the oxidation of the reduced coenzyme Q10 and can be store...
|
|
WO/2023/121251A1 |
The present disclosure pertains to a compound useful for treating or palliating fibrosis, especially pulmonary fibrosis and a medical use thereof.
|
|
WO/2023/121519A1 |
The invention relates to the field of pharmaceuticals and medicine and concerns the use of 1-[2-(1-methylimidazole-4-yl)-ethyl]perhydroazine-2,6-dione or its pharmaceutically acceptable salts for the treatment and/or prophylaxis of COVID...
|
|
WO/2023/120555A1 |
The present description discloses a favorable means for suppressing oxidation of reduced coenzyme Q10 (QH) without requiring formulation of QH. At least one embodiment of the present invention relates to a method for storing reduced co...
|
|
WO/2023/120378A1 |
The purpose of the present invention is to provide an oral composition containing ergothioneine or a salt thereof and at least one arachidonic acid, the oral composition such that the bitterness derived from ergothioneine or salts thereo...
|
|
WO/2023/120367A1 |
The purpose of the present invention is to provide an oral composition which contains ergothioneine or a salt thereof and in which the bitterness derived from ergothioneine or a salt thereof is reduced. The present invention pertains to ...
|
|
WO/2023/120331A1 |
In the present invention, an anticancer drug/prodrug is used in a combination therapy with radiotherapy. In the chemical formula representing the same, the moiety in which R1 and R2 are bonded to an N atom results from the removal of an ...
|
|
WO/2023/115149A1 |
This invention relates to compounds of formula (X) and salts, solvates, tautomers, N-oxides, stereoisomers, polymorphs and/or prodrugs thereof. Also disclosed is the use of the compounds of formula (X) to treat necroptosis, and/or inhibi...
|
|
WO/2023/120408A1 |
The purpose of the present invention is to provide a composition for suppressing or ameliorating cognitive function decline. The present invention pertains to a composition for suppressing or ameliorating cognitive function decline, the ...
|
|
WO/2023/115116A1 |
The present invention relates to polynucleotides for the generation of genetically modified plants, algae or plastids thereof that are capable of producing cannabinoids. In an aspect, the present invention also relates to methods of prod...
|
|
WO/2023/115150A1 |
This invention relates to compounds of formula (X) and salts, solvates, tautomers, N-oxides, stereoisomers, polymorphs and/or prodrugs thereof. Also disclosed is the use of the compounds of formula (X) to treat necroptosis and/or inhibit...
|
|
WO/2023/120368A1 |
The purpose of the present invention is to provide an oral composition which contains ergothioneine or a salt thereof and at least one eicosapentaenoic acid and in which the bitterness derived from ergothioneine or the salt thereof and t...
|
|
WO/2023/120370A1 |
The purpose of the present invention is to provide: an oral composition containing ergothioneine or a salt thereof and vitamin E and having minimized bitterness resulting from ergothioneine or a salt thereof and odor resulting from vitam...
|
|
WO/2023/117189A1 |
The invention relates to a composition for use in a method of treating a bacterial infection selected from a bacterial urinary tract infection, a bacterial respiratory tract infection, a bacterial soft tissue infection and a bacterial bo...
|
|
WO/2023/120553A1 |
The present description discloses a preferred means for preventing the oxidation of reduced coenzyme Q10 (QH) without requiring the formulation of QH into a preparation. One or more embodiments of the present invention relates to: a me...
|
|
WO/2023/120658A1 |
An enzyme according to the present invention has activity to convert uridine in RNA to cytidine. A complex according to the present invention comprises said enzyme and a sequence recognition module that causes uridine generated in mRNA b...
|
|
WO/2022/081795A9 |
A long-term delivery system for age-related macular degeneration (AMD) that can address the multifactorial nature of the disease. A polyurethane nanocapsule is disclosed that includes encapsulated molecules that treat AMD. The molecules ...
|
|
WO/2023/112657A1 |
The present invention provides a stabilizer that can suppress heat-induced hydrolysis of a nicotinamide mononucleotide. A stabilizer according to the present invention is for a nicotinamide mononucleotide and is characterized by compri...
|
|
WO/2023/112975A1 |
Provided is a lymphocyte function promoter. The lymphocyte function promoter contains at least one selected from the group consisting of a compound represented by general formula (1), a salt thereof, and a solvate of the same.
|
|
WO/2023/113540A1 |
The present invention provides novel monohydrochloride of (2R, 3S)-2-(3-(4,5-dichloro-1H-benzo[d]imidazol-1-yl)propyl)piper
idin-3-ol, oxalate of (2R, 3S)-2-(3-(4,5-dichloro-1H-benzo[d]imidazol-1-yl)propyl)piper
idin-3-ol, maleate of (2R...
|
|
WO/2023/113278A1 |
The present invention relates to: an anti-stress composition comprising at least one extract selected from the group consisting of peppermint extract and perilla frutescens extract as a natural extract mixture; and a use thereof. Using p...
|
|
WO/2023/113023A1 |
The present invention provides: a compound that has an inhibitory action against hematopoietic prostaglandin D synthase (H-PGDS), and thus is useful for the prevention and treatment of diseases in which the enzyme is involved; and a phar...
|
|
WO/2023/112912A1 |
The purpose of the present invention is to provide a conjugate compound capable of inhibiting complement activation. The conjugate compound contains: a polymer (A) which has a constitutional unit derived from a monomer (a) having two or ...
|
|
WO/2023/115060A1 |
Provided herein are psychoplastogens which can be useful for treating hearing loss.
|
|
WO/2023/112454A1 |
Provided are: an intestinal tumor suppressor which comprises a dectin-1inhibitor or β-glucan having a dectin-1 inhibition activity and can suppress intestinal tumor through the inhibition of dectin-1; a PGE2 production inhibitor which c...
|
|
WO/2023/111084A1 |
The present invention relates to nucleic acid molecules encoding Lamin A, vectors, AAV and pharmaceutical compositions comprising said nucleic acid molecules for use in treatment of laminopathies.
|
|
WO/2023/112974A1 |
Provided is a hypertension-improving agent that contains a seaweed extract in a smaller amount, compared to a preset amount of the seaweed extract for achieving a blood pressure-improving effect, and yet can exhibit an effect equivalent ...
|
|
WO/2023/112965A1 |
Provided is an excellent drug capable of increasing antimicrobial resistance against multi-drug resistant Pseudomonas aeruginosa. The present invention relates to a VHH antibody capable of recognizing loop 1 or loop 2 in OprM of a RND-...
|
|
WO/2023/106421A1 |
Provided is an expression inhibition agent for a TRPC6 protein, the expression inhibition agent including staple nucleic acids for the TRPC6 gene.
|
|
WO/2023/107448A1 |
Disclosed are compositions containing cannabinoid, cannabidiol, cannabidiol isomer, or cannabidiol analog and combinations thereof for treating oxidative stress and diminishing the signs of aging. In one aspect, a composition comprising ...
|
|
WO/2023/107938A1 |
The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament f...
|
|
WO/2023/106325A1 |
The purpose of the present invention is to provide a means for inhibiting intestinal absorption of β-alanine. This problem can be solved by the β-alanine absorption inhibitor of the present invention that comprises, as an active ingr...
|
|
WO/2023/106947A1 |
The invention concerns 2-methoxyestradiol to be used in the treatment of mastocytosis, in particular its skin form and/or systemic form.
|
|
WO/2023/106273A1 |
The present invention addresses the problem of developing a composition having antiviral activity by utilizing the immunological action of intestinal bacteria as well as the action thereof against infection with viruses including influen...
|
|
WO/2023/105898A1 |
The present invention provides an antisense oligonucleotide complex which includes an antisense oligonucleotide and a complementary strand which includes a sequence which is complementary to said antisense oligonucleotide, said complex b...
|
|
WO/2023/106248A1 |
The present invention addresses the problems of: providing a prophylactic agent, a therapeutic agent or a therapeutic composition for steatohepatitis, such as progressive familial intrahepatic cholestasis type 1 (PFIC1), caused by a defi...
|
|
WO/2023/106319A1 |
The present invention provides a vaccine composition which contains a complex of a T-cell receptor antigen peptide and a B-cell receptor antigen peptide and which can induce the production of an antibody against IL-23, wherein the B-cell...
|
|
WO/2023/102664A1 |
The present invention concerns a method for extending telomeres that have decayed in length without engaging bodily functions such as telomerase, so as to prevent cells from reaching the Hayflick limit and thus avoid risk of becoming sen...
|
|
WO/2023/104213A1 |
The present invention provides a cyclic bisbenzyl tetrahydroisoquinoline compound as represented by formula (I), and a pharmaceutically acceptable salt, an enantiomer, a diastereoisomer, a racemate, a crystalline hydrate, and a solvate t...
|
|
WO/2023/106310A1 |
The present invention pertains to: a compound, or a pharmacologically acceptable salt thereof, having GLP-1 receptor agonist activity and offering utility as an agent for treating or preventing diseases involving GLP-1 receptors; and a p...
|
|
WO/2023/106376A1 |
The purpose of the present invention is to provide a novel material that promotes the production of collagen and/or hyaluronic acid and/or activates human epidermal keratinocytes. A lactic acid bacterium belonging to the genus Fructobaci...
|
|
WO/2023/102111A1 |
The present disclosure provides methods, uses, kits, and compositions comprising a compound of Formula (I), and either a second compound of Formula (I) or a compound of Formula (II). In one aspect, the methods are for treating a neurolog...
|
|
WO/2023/099902A1 |
An ion channel modulator for use in the treatment of cancer and/or metastasis is provided. The ion channel modulator is capable of facilitating ion flow through sodium leak channel (NALCN). A pharmaceutical composition comprising an ion ...
|
|
WO/2023/101441A1 |
The present invention relates to a use of microsomal triglyceride transfer protein (MTP) inhibitor in the treatment of fibrosis disease and, more specifically, to a novel use of an MTP inhibitor which exhibits an inhibitory effect on the...
|
|
WO/2023/100925A1 |
Provided is an asymmetric cell division inhibitor with which infertility due to aging or the like can be ameliorated. The asymmetric cell division inhibitor includes a spontaneous activation inhibitor that inhibits asymmetric cell divi...
|
|
WO/2023/100691A1 |
The present disclosure relates to providing a substance and a composition that promote the proliferation of epidermal stem cells and are effective in improving wrinkles and barrier function from the viewpoint of maintaining or improving ...
|
|
WO/2023/100829A1 |
The present invention provides a novel MuSK antibody. The present invention provides a molecule which binds to a target antigen, and is characterized by comprising a region that binds to the target antigen, a first peptide that recogni...
|
